<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640079</url>
  </required_header>
  <id_info>
    <org_study_id>15-001761</org_study_id>
    <nct_id>NCT02640079</nct_id>
  </id_info>
  <brief_title>A Behavioral Intervention for Pain Catastrophizing in Primary Dysmenorrhea</brief_title>
  <official_title>A Behavioral Intervention for Pain Catastrophizing in Primary Dysmenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the feasibility and efficacy of a brief group therapy
      treatment program focused on reducing pain catastrophizing in adolescents and young adults
      (ages 16-25) with menstrual pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility (as determined by attrition rate)</measure>
    <time_frame>After each cohort completes their 5 group CBT sessions; 1 week after the 5th and final CBT session in each cohort</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability - participants' views of the intervention's 1) appeal; 2) helpfulness; and 3) ease of participation</measure>
    <time_frame>Assessed via qualitative interviews which will occur during each participant's post-intervention lab assessment (i.e., during the first two days of the first menstrual period after intervention completion)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pain catastrophizing</measure>
    <time_frame>Assessed via questionnaire completed at six time points: pre-intervention lab session, immediately following the completion of the 5th group CBT session, post-intervention lab session, and once a month for three months after intervention completion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in menstrual pain level assessed via 11-point numeric rating scale (NRS)</measure>
    <time_frame>Assessed via questionnaire completed at six time points: pre-intervention lab session, immediately following the completion of the 5th group CBT session, post-intervention lab session, and once a month for three months after intervention completion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in medication use (dosage and frequency of pain medication use)</measure>
    <time_frame>Assessed via questionnaire completed at six time points: pre-intervention lab session, immediately following the completion of the 5th group CBT session, post-intervention lab session, and once a month for three months after intervention completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in menstrual symptoms as assessed by the Menstrual Symptom Questionnaire (MSQ)</measure>
    <time_frame>Assessed via questionnaire completed at six time points: pre-intervention lab session, immediately following the completion of the 5th group CBT session, post-intervention lab session, and once a month for three months after intervention completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety as assessed by the Brief Symptom Inventory 18 (BSI-18)</measure>
    <time_frame>Assessed via questionnaire completed at six time points: pre-intervention lab session, immediately following the completion of the 5th group CBT session, post-intervention lab session, and once a month for three months after intervention completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression as assessed by the Brief Symptom Inventory 18 (BSI-18)</measure>
    <time_frame>Assessed via questionnaire completed at six time points: pre-intervention lab session, immediately following the completion of the 5th group CBT session, post-intervention lab session, and once a month for three months after intervention completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in somatization as assessed by the Brief Symptom Inventory 18 (BSI-18)</measure>
    <time_frame>Assessed via questionnaire completed at six time points: pre-intervention lab session, immediately following the completion of the 5th group CBT session, post-intervention lab session, and once a month for three months after intervention completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in temporal summation (TS)</measure>
    <time_frame>Assessed at pre- and post-intervention lab sessions, each of which will occur during the first 2 days of menstruation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in conditioned pain modulation (CPM): pain ratings in response to a heat stimulus prior to and after administration of a conditioning pain stimulus (cold water)</measure>
    <time_frame>Assessed at pre- and post-intervention lab sessions, each of which will occur during the first 2 days of menstruation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Galvanic Skin Response (GSR)</measure>
    <time_frame>Assessed at pre- and post-intervention lab sessions, each of which will occur during the first 2 days of menstruation; GSR assessed at rest (5 min), during four pain induction tasks (3-5 min each), and again at rest (5 min)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate Variability (HRV)</measure>
    <time_frame>Assessed at pre- and post-intervention lab sessions, each of which will occur during the first 2 days of menstruation; HRV assessed at rest (5 min), during four pain induction tasks (3-5 min each), and again at rest (5 min)</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pain Catastrophizing</condition>
  <condition>Primary Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Cognitive behavioral therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitive behavioral therapy aimed at reducing pain catastrophizing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral therapy</intervention_name>
    <arm_group_label>Cognitive behavioral therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female ages 16-25 years

          -  Self-reported menstrual cycle averaging 24-32 days

          -  Menstrual pain rating of ≥4 on the Numeric Rating Scale for at least the previous
             three menstrual cycles prior to participation

          -  Written informed consent or assent (if a minor, parent must also provide written
             parental permission)

          -  Able to read and understand English

        Exclusion Criteria:

          -  Use of oral contraceptives or any exogenous hormones in the previous 3 months

          -  Presence of persistent pelvic pain throughout the menstrual cycle

          -  Acute illness or injury that may impact lab performance or that affects sensitivity of
             the extremities

          -  Diagnosis of an underlying medical cause for dysmenorrhea symptoms

          -  No or minimal menstrual pain (NRS rating of ≤ 3) during any of the 3 previous cycles
             prior to study participation

          -  Daily use of opioids; participants using other analgesics will be included, but will
             be asked not to take these analgesics on the days of the lab sessions

          -  Developmental delay, autism, or significant anatomic impairment that may preclude
             understanding of study procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Laura A Payne, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Laura Payne</investigator_full_name>
    <investigator_title>Adjunct Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Cognitive behavioral therapy</keyword>
  <keyword>Laboratory pain responsivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

